CoChat

Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 19 of the 66 sources its claims cite were checked for support.

Abstract

Emerging data demonstrate that the activity of immune cells can be modulated by microbial molecules. Here, we show that the short-chain fatty acids (SCFAs) pentanoate and butyrate enhance the anti-tumor activity of cytotoxic T lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells through metabolic and epigenetic reprograming. We show that in vitro treatment of CTLs and CAR T cells with pentanoate and butyrate increases the function of mTOR as a central cellular metabolic sensor, and inhibits class I histone deacetylase activity. This reprogramming results in elevated production of effector molecules such as CD25, IFN-γ and TNF-α, and significantly enhances the anti-tumor activity of antigen-specific CTLs and ROR1-targeting CAR T cells in syngeneic murine melanoma and pancreatic cancer models. Our data shed light onto microbial molecules that may be used for enhancing cellular anti-tumor immunity. Collectively, we identify pentanoate and butyrate as two SCFAs with therapeutic utility in the context of cellular cancer immunotherapy.

Overview

CoChat Summary

TL;DR

The paper shows that the microbial short-chain fatty acids pentanoate and butyrate enhance the anti-tumor activity of cytotoxic T lymphocytes and chimeric antigen receptor T cells through metabolic and epigenetic reprogramming. It identifies these SCFAs as potential tools for improving adoptive cancer immunotherapy.

Key findings

  • Among 16 human commensals tested, the two *Megasphaera massiliensis* strains DSM 26228 and NCIMB 42787 were the only strong producers of both pentanoate and butyrate; *M. elsdenii* also produced pentanoate but at lower levels, while *F. prausnitzii* and *A. hadrus* produced high butyrate.
  • Pentanoate and butyrate increased IFN-γ+TNF-α+ CTLs and TNF-α secretion, inhibited class I HDAC enzymes but not class II HDACs, increased mTOR and S6 phosphorylation and ECAR, and acted independently of GPR41/GPR43.
  • Ex vivo pretreatment with pentanoate or butyrate improved anti-tumor immunity in B16OVA melanoma, with decreased tumor volume and weight and higher transferred CD8+ T cells producing IFN-γ and TNF-α in draining lymph nodes; pentanoate-treated OT-I CTLs abrogated PancOVA tumor growth and persisted after remission.
  • Pentanoate and butyrate enhanced murine ROR1-CAR T cells (CD25, TNF-α, IFN-γ; reduced tumor volume and weight) and human ROR1-CAR T cells (CD25, IL-2, IFN-γ, TNF-α, proliferation, cytolysis); however, in vivo pentanoate administration did not enhance anti-tumor immunity or anti-PD-1 therapy.

Methods

  • Murine and human CD8+ T cells, CTLs, and CAR T cells were cultured with SCFAs (e.g., 0.75 mM butyrate and 2.5 mM pentanoate for murine CAR T cells; 1 mM butyrate and 4 mM pentanoate for human CD8+ T cells) or HDAC inhibitors; bacterial supernatants from 16 commensals were analyzed by GC-MS, and HDAC activity, ECAR, ELISA, and flow cytometry were used.
  • In vivo, B16OVA, PancOVA, or Panc02/ROR1 tumors were injected s.c. into CD45.2+ mice, followed by adoptive transfer of CD45.1+ OT-I CTLs or ROR1-CAR T cells on day 5; tumor volume/weight and T cell responses were analyzed, with persistence studied in Rag1-deficient mice co-transferred with Tregs and Foxp3−CD4+ T cells.
  • Statistical analysis used two-tailed unpaired Student’s t-test and, for multiple groups, a linear-mixed effects model with Tukey correction; p < 0.05 was considered significant.

Limitations

  • The paper states that involvement of other microbial metabolites in supernatant effects cannot be excluded, that clinical implementation of SCFA administration requires further investigation of optimal route, dosing, and schedule to balance effector versus regulatory immune subsets, and that the complex crosstalk between SCFA-mediated epigenetic changes and metabolic effects should be investigated further.
  • Evident from the text: most mechanistic and efficacy data are from murine models and in vitro human CAR T cells, with no human clinical trial data; systemic in vivo pentanoate did not enhance anti-tumor immunity or anti-PD-1 therapy, so the therapeutic benefit shown is mainly from ex vivo pretreatment.
  • Evident from the text: several experiments used small samples, such as n = 3 mice or three human donors, which limits generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-021-24331-1

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Microbiota-derived SCFAs promote the production of effector cytokines in CTLs. a The production of SCFAs, branched-chain fatty acids (BCFAs) and medium-chain fatty acids (MCFAs) by 16 human commensals was measured by GC-MS. All bacteria were grown in vitro until the stationary growth phase before the measurement of fatty acids in supernatants (n = 3 independent experiments). b The frequency of IFN-γ- and TNF-α-expressing CD8+ T cells cultured under suboptimal CTL conditions and stimulated with supernatant derived from M. massiliensis (1:40 or 1:20 supernatant-to-cell media ratios; n = 3 mice). c The percentage of IFN-γ+TNF-α+ CTLs, derived from SPF mice and treated with the indicated SCFAs for three days (n = 3 mice). d The secretion of TNF-α from CTLs treated with SCFAs was determined by ELISA (n = 3 mice). Statistical analysis was performed by two-tailed unpaired Student’s t-test; mean ± s.e.m. values are presented. Source data are provided as a Source data file.
Fig. 1 Microbiota-derived SCFAs promote the production of effector cytokines in CTLs. a The production of SCFAs, branched-chain fatty acids (BCFAs) and medium-chain fatty acids (MCFAs) by 16 human commensals was measured by GC-MS. All bacteria were grown in vitro until the stationary growth phase before the measurement of fatty acids in supernatants (n = 3 independent experiments). b The frequency of IFN-γ- and TNF-α-expressing CD8+ T cells cultured under suboptimal CTL conditions and stimulated with supernatant derived from M. massiliensis (1:40 or 1:20 supernatant-to-cell media ratios; n = 3 mice). c The percentage of IFN-γ+TNF-α+ CTLs, derived from SPF mice and treated with the indicated SCFAs for three days (n = 3 mice). d The secretion of TNF-α from CTLs treated with SCFAs was determined by ELISA (n = 3 mice). Statistical analysis was performed by two-tailed unpaired Student’s t-test; mean ± s.e.m. values are presented. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 2 Pentanoate inhibits the class I HDAC enzymes and enhances the activity of mTOR in CD8+ T cells. a Impact of bacterial SCFAs, BCFAs, and MCFAs on the activity of recombinant class I and II HDAC enzymes. TSA was used as a control pan-HDAC inhibitor. One of three independent experiments is shown. b The fluorogenic HDAC assay was applied to measure the HDAC inhibitory activity of SCFAs on CTLs. The value for unstimulated CTLs was arbitrarily set to 1.0. Four independent experiments were performed (analyzed by two-tailed unpaired Student’s t-test; data are shown as mean ± s.e.m). c–e Murine CD8+ T cells were polarized under suboptimal CTL-inducing conditions for three days. Representative contour plots (c) and bar graphs (d) indicate the frequency of IFN-γ+TNF-α+ cells and TNF-α secretion (e) after treatment with 300 nM mocetinostat (class I HDAC inhibitor) or 2.5 µM TMP-195 (class II HDAC inhibitor), respectively (n = 3 mice, analyzed by two-tailed unpaired Student’s t-test; data are shown as mean ± s.e.m). f Murine CTLs were cultured in medium containing 1.0% serum and treated with indicated HDACi for three days. Representative histogram plots and bar graphs indicate the phoshorylated levels of mTOR and S6 ribosomal protein, respectively (n = 3 mice, analyzed by two-tailed unpaired Student’s t-test; data are shown as mean ± s.e.m). Source data are provided as a Source data file.
Fig. 2 Pentanoate inhibits the class I HDAC enzymes and enhances the activity of mTOR in CD8+ T cells. a Impact of bacterial SCFAs, BCFAs, and MCFAs on the activity of recombinant class I and II HDAC enzymes. TSA was used as a control pan-HDAC inhibitor. One of three independent experiments is shown. b The fluorogenic HDAC assay was applied to measure the HDAC inhibitory activity of SCFAs on CTLs. The value for unstimulated CTLs was arbitrarily set to 1.0. Four independent experiments were performed (analyzed by two-tailed unpaired Student’s t-test; data are shown as mean ± s.e.m). c–e Murine CD8+ T cells were polarized under suboptimal CTL-inducing conditions for three days. Representative contour plots (c) and bar graphs (d) indicate the frequency of IFN-γ+TNF-α+ cells and TNF-α secretion (e) after treatment with 300 nM mocetinostat (class I HDAC inhibitor) or 2.5 µM TMP-195 (class II HDAC inhibitor), respectively (n = 3 mice, analyzed by two-tailed unpaired Student’s t-test; data are shown as mean ± s.e.m). f Murine CTLs were cultured in medium containing 1.0% serum and treated with indicated HDACi for three days. Representative histogram plots and bar graphs indicate the phoshorylated levels of mTOR and S6 ribosomal protein, respectively (n = 3 mice, analyzed by two-tailed unpaired Student’s t-test; data are shown as mean ± s.e.m). Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 3 Pentanoate enhances anti-tumor activity of antigen-specific CTLs. a Experimental design for the role of SCFAs in promoting anti-tumor immunity. b–g After three days of pretreatment with indicated HDAC inhibitors, CD8+CD45.1+ OVA-specific CTLs were transferred intraperitoneally (i.p.) into CD45.2+ mice bearing 5-days old B16OVA tumors. Tumor volume (b) and tumor mass (c) were analyzed on day 14 after inoculation of tumor cells (n = 6 mice/group combined from two independent experiments). The t-SNE plots in (d) show CD8+CD45.1+ cells among lymphocytes from the tumor-draining LNs. The percentage (e) and total cell number (f) of transferred CD8+CD45.1+ OT-I CTLs in the tumor-draining LNs at day 14 after tumor inoculation are shown. In g the total cell numbers of transferred antigen-specific IFN-γ+TNF-α+ CTLs were examined on day 14 after inoculation of B16OVA tumors in tumor-draining LNs (in e–g, n = 6 mice/group combined from two independent experiments). h–j OVA-specific CD45.1+ CTLs pretreated with pentanoate were adoptively transferred into CD45.2+ mice bearing 5-days old PancOVA tumors. Tumor volume (h) and tumor weight (i) were determined on day 23 post tumor inoculation. In j frequencies of transferred IFN-γ-producing CD8+ T cells in draining LNs and spleens were analyzed on day 23 post tumor inoculation (n = 6 mice/group combined from two independent experiments). Multiple group comparison (b, h) was performed by a linear-mixed effects model with Tukey correction. The two-tailed unpaired Student’s t-test was applied to compare two groups (n.s. = not significant; results are shown as mean ± s.e.m). Source data are provided as a Source data file.
Fig. 3 Pentanoate enhances anti-tumor activity of antigen-specific CTLs. a Experimental design for the role of SCFAs in promoting anti-tumor immunity. b–g After three days of pretreatment with indicated HDAC inhibitors, CD8+CD45.1+ OVA-specific CTLs were transferred intraperitoneally (i.p.) into CD45.2+ mice bearing 5-days old B16OVA tumors. Tumor volume (b) and tumor mass (c) were analyzed on day 14 after inoculation of tumor cells (n = 6 mice/group combined from two independent experiments). The t-SNE plots in (d) show CD8+CD45.1+ cells among lymphocytes from the tumor-draining LNs. The percentage (e) and total cell number (f) of transferred CD8+CD45.1+ OT-I CTLs in the tumor-draining LNs at day 14 after tumor inoculation are shown. In g the total cell numbers of transferred antigen-specific IFN-γ+TNF-α+ CTLs were examined on day 14 after inoculation of B16OVA tumors in tumor-draining LNs (in e–g, n = 6 mice/group combined from two independent experiments). h–j OVA-specific CD45.1+ CTLs pretreated with pentanoate were adoptively transferred into CD45.2+ mice bearing 5-days old PancOVA tumors. Tumor volume (h) and tumor weight (i) were determined on day 23 post tumor inoculation. In j frequencies of transferred IFN-γ-producing CD8+ T cells in draining LNs and spleens were analyzed on day 23 post tumor inoculation (n = 6 mice/group combined from two independent experiments). Multiple group comparison (b, h) was performed by a linear-mixed effects model with Tukey correction. The two-tailed unpaired Student’s t-test was applied to compare two groups (n.s. = not significant; results are shown as mean ± s.e.m). Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 4 Pentanoate-treatment enhances the anti-tumor activity of murine CAR T cells. a Experimental design for the analysis of SCFA-treated ROR1-specific murine CD8+ CAR T cells (CARROR1). b The surface expression of CD25 on CAR T cells was measured by flow cytometry analysis after three days of stimulation with butyrate or pentanoate (n = 3 independent experiments). c, d The production of TNF-α and IFN-γ from CAR T cells was measured by ELISA (c) and flow cytometry analysis (d) after three days of stimulation with butyrate or pentanoate. Three similar experiments were performed. e–g Following the pretreatment with pentanoate for three days, ROR1-specific CAR T cells were transferred i.p. into mice bearing 5-days old PancROR1 tumors. Tumor volume (e) and tumor mass (f) were analyzed on day 14 post tumor inoculation (n = 6 mice/group combined from two independent experiments). The percentage and total cell number of transferred TNF-α+ and IFN-γ+ CAR T cells in the tumor tissue at day 14 after tumor inoculation are shown in (g). For all experiments, 0.75 mM butyrate and 2.5 mM pentanoate were used, respectively. Multiple group comparison in (e) was performed by a linear-mixed effects model with Tukey correction. In b–d and f, g, the two-tailed unpaired Student’s t-test was applied. Source data are provided as a Source data file.
Fig. 4 Pentanoate-treatment enhances the anti-tumor activity of murine CAR T cells. a Experimental design for the analysis of SCFA-treated ROR1-specific murine CD8+ CAR T cells (CARROR1). b The surface expression of CD25 on CAR T cells was measured by flow cytometry analysis after three days of stimulation with butyrate or pentanoate (n = 3 independent experiments). c, d The production of TNF-α and IFN-γ from CAR T cells was measured by ELISA (c) and flow cytometry analysis (d) after three days of stimulation with butyrate or pentanoate. Three similar experiments were performed. e–g Following the pretreatment with pentanoate for three days, ROR1-specific CAR T cells were transferred i.p. into mice bearing 5-days old PancROR1 tumors. Tumor volume (e) and tumor mass (f) were analyzed on day 14 post tumor inoculation (n = 6 mice/group combined from two independent experiments). The percentage and total cell number of transferred TNF-α+ and IFN-γ+ CAR T cells in the tumor tissue at day 14 after tumor inoculation are shown in (g). For all experiments, 0.75 mM butyrate and 2.5 mM pentanoate were used, respectively. Multiple group comparison in (e) was performed by a linear-mixed effects model with Tukey correction. In b–d and f, g, the two-tailed unpaired Student’s t-test was applied. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 5 Pentanoate enhances the functional status of human CAR T cells. a CD8+ T cells were isolated from peripheral blood of healthy donors were differentiated into CTLs in presence or absence of butyrate (1 mM), pentanoate (4 mM), mocetinostat (HDAC class I inhibitor, 300 nM) or TMP-195 (HDAC class II inhibitor, 2.5 µM). Representative contour plots (left) and graphs (right) show the frequency of IFN-γ+ TNF-α+ CD8+ T cells. (n = 4 combined from four independent experiments). b Experimental setup for the functional analysis of pentanoate-treated ROR1-specific human CD8+ CAR T cells (CARROR1 T cells). c The surface expression of CD25 was measured following pentanoate treatment by flow cytometry. d The secretion of IL-2 was detected in supernatants of pentanoate-treated CARROR1 T cells by ELISA. e The secretion of IFN-γ and TNF-α was analyzed in supernatants of pentanoate-treated CARROR1 T cells by ELISA. f, g Proliferation of CARROR1 T cells was determined by CFSE labeling (f). CARROR1 T cells pretreated with pentanoate were stained with CFSE and subsequently co-cultured with K562ROR1 cells in the absence of pentanoate. CD8+ T cells without the CAR construct were used as mock control cells. The cytolytic activity of CARROR1 T cells was examined by analysis of specific lysis following encounter with luciferase-expressing K562ROR1 cells (g). The percentage of lysed target cells was determined in 1 h intervals (effector-to-target cell (E:T) ratio = 2.5:1). Data points shown in the graphs represent CARROR1 T cells derived from three different donors (c–g). Following pentanoate pretreatment, the stimulation was mediated by co-culture of CD8+ CARROR1 T cells with ROR1-expressing K562 (K562ROR1) cells in the absence of pentanoate. The groups in a and c–g were compared by two-tailed unpaired Student’s t-test, data shown as mean ± s.e.m. Source data are provided as a Source data file.
Fig. 5 Pentanoate enhances the functional status of human CAR T cells. a CD8+ T cells were isolated from peripheral blood of healthy donors were differentiated into CTLs in presence or absence of butyrate (1 mM), pentanoate (4 mM), mocetinostat (HDAC class I inhibitor, 300 nM) or TMP-195 (HDAC class II inhibitor, 2.5 µM). Representative contour plots (left) and graphs (right) show the frequency of IFN-γ+ TNF-α+ CD8+ T cells. (n = 4 combined from four independent experiments). b Experimental setup for the functional analysis of pentanoate-treated ROR1-specific human CD8+ CAR T cells (CARROR1 T cells). c The surface expression of CD25 was measured following pentanoate treatment by flow cytometry. d The secretion of IL-2 was detected in supernatants of pentanoate-treated CARROR1 T cells by ELISA. e The secretion of IFN-γ and TNF-α was analyzed in supernatants of pentanoate-treated CARROR1 T cells by ELISA. f, g Proliferation of CARROR1 T cells was determined by CFSE labeling (f). CARROR1 T cells pretreated with pentanoate were stained with CFSE and subsequently co-cultured with K562ROR1 cells in the absence of pentanoate. CD8+ T cells without the CAR construct were used as mock control cells. The cytolytic activity of CARROR1 T cells was examined by analysis of specific lysis following encounter with luciferase-expressing K562ROR1 cells (g). The percentage of lysed target cells was determined in 1 h intervals (effector-to-target cell (E:T) ratio = 2.5:1). Data points shown in the graphs represent CARROR1 T cells derived from three different donors (c–g). Following pentanoate pretreatment, the stimulation was mediated by co-culture of CD8+ CARROR1 T cells with ROR1-expressing K562 (K562ROR1) cells in the absence of pentanoate. The groups in a and c–g were compared by two-tailed unpaired Student’s t-test, data shown as mean ± s.e.m. Source data are provided as a Source data file.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 0 Not valid · 28 Not checked · 81 Own results and interpretations

71 more claims

Create a free account to see all 122 claims and to verify the 47 references still open.

See all claims — free account
  • It may state two separate claims as one. 27
  • Probably not a substantial claim. 27

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 47 references

Cited by

See all 838

Metadata

Authors
Luu, M., Riester, Z., Baldrich, A., Reichardt, N., Yuille, S., Busetti, A., Klein, M., Wempe, A., Leister, H., Raifer, H., Picard, F., Muhammad, K., Ohl, K., Romero, R., Fischer, F., Bauer, C. A., Huber, M., Gress, T. M., Lauth, M., Danhof, S., Bopp, T., Nerreter, T., Mulder, I. E., Steinhoff, U., Hudecek, M., & Visekruna, A.
Affiliations
  • Philipps University of Marburg (DE)
  • Universitätsklinikum Würzburg (DE)
  • Johannes Gutenberg University Mainz (DE)
  • United Arab Emirates University (AE)
  • RWTH Aachen University (DE)
Corresponding author
  • Hudecek, Michael
  • Visekruna, Alexander
Venue
Nature Communications
Published
2021-07-01
Volume
12
Issue
1
Pages
4077-4077
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3175895832
Cited by
771
References
47
Citations by year
2026: 193 · 2025: 217 · 2024: 157 · 2023: 118 · 2022: 79 · 2021: 7
FWCI
33.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
  • RWTH Publications (RWTH Aachen) (submittedVersion, other-oa)
  • RWTH Publications (RWTH Aachen)
Funders
Deutsche Forschungsgemeinschaft (DFG-KFO325)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
short-chain fatty acids, butyrate, CD8+ T cells, cytotoxic T lymphocytes, chimeric antigen receptor T cells, ROR1, adoptive immunotherapy, cancer immunotherapy, mTOR signaling, histone deacetylase, epigenetic reprogramming, cellular metabolism, melanoma, pancreatic cancer, antitumor immunity
MeSH terms
Animals, Butyrates, Fatty Acids, Volatile, Female, Immunologic Factors, Immunotherapy, Interferon-gamma, Melanoma, Mice, Inbred C57BL, Neoplasms, Peptide Fragments, T-Lymphocytes, Cytotoxic, Tumor Necrosis Factor-alpha, Cytokines, Immunotherapy, Adoptive, CD8-Positive T-Lymphocytes, Receptors, G-Protein-Coupled, Cell Line, Tumor, Megasphaera, Mice, Interleukin-2 Receptor alpha Subunit, Receptor Tyrosine Kinase-like Orphan Receptors, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. https://app.cochat.ai/papers/10.1038/s41467-021-24331-1
The paper
Luu, M., Riester, Z., Baldrich, A., Reichardt, N., Yuille, S., Busetti, A., Klein, M., Wempe, A., Leister, H., Raifer, H., Picard, F., Muhammad, K., Ohl, K., Romero, R., Fischer, F., Bauer, C. A., Huber, M., Gress, T. M., Lauth, M., . . . Visekruna, A. (2021). Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nature Communications. https://doi.org/10.1038/s41467-021-24331-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.